Nanoparticle albumin-bound-paclitaxel in the treatment of metastatic urethral adenocarcinoma: The significance of molecular profiling and targeted therapy - Abstract

Primary urethral cancer is rare and accounts for only 0.003% of all malignancies arising from the female genitourinary tract.

Due to the rarity of this disease, no consensus exists regarding the optimal therapeutic approach. Nanoparticle albumin-bound-paclitaxel has been shown to be effective in the treatment of a number of malignancies including metastatic breast, pancreatic, and bladder cancer. We present a 67-year-old woman with advanced metastatic urethral adenocarcinoma resistant to two lines of chemotherapy (ifosfamide/paclitaxel/cisplatin and irinotecan/5-fluorouracil/leucovorin) that showed a dramatic response to nanoparticle albumin-bound-paclitaxel. This is the first case report to document the use and efficacy of nanoparticle albumin-bound-paclitaxel in the treatment of unresectable metastatic urethral cancer.

Written by:
Abaza YM, Alemany C.   Are you the author?
Department of Internal Medicine, Florida Hospital, Orlando, FL 32804, USA; Cancer Institute of Florida, Florida Hospital, 2501 North Orange Avenue, Suite 689, Orlando, FL 32804, USA.

Reference: Case Rep Urol. 2014;2014:489686.
doi: 10.1155/2014/489686


PubMed Abstract
PMID: 25202467

UroToday.com Penile and Urethral Cancers Section